Neuren Pharmaceuticals shares an update on the the company's Angelman Syndrome Clinical Study. July 8, 2023
Ann: Neuren commences Phase 2 trial of NNZ-2591 in Angelman, page-18
-
- There are more pages in this discussion • 13 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$13.75 |
Change
-0.175(1.26%) |
Mkt cap ! $1.761B | |||
| Open | High | Low | Value | Volume |
| $13.94 | $13.96 | $13.50 | $3.260M | 238.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 10 | 310 | $13.74 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $13.75 | 366 | 16 |
View Market Depth
| Last trade - 14.06pm 06/09/2024 (20 minute delay) ? |
| NEU (ASX) Chart |